Alaunos Therapeutics, Inc.: 5%+ holders

As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Alaunos Therapeutics, Inc. The largest reported stake is Fairmount Funds Management LLC's, at 19.99%. 11 filings are on record since July 1, 2025 (Schedule 13D, October 15, 2026).

Who owns Alaunos Therapeutics, Inc.?

Strategic EP, LLC also filed stake reports on 6 other companies ↓

Sell to companies like Alaunos Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-10-15 · Reporting person: Fairmount Funds Management LLC · Sole voting: 0 · Shared voting: 858,789 · Sole dispositive: 0 · Shared dispositive: 858,789 · SCHEDULE 13D, 2026-10-15
• Filing 2026-10-15 · Reporting person: WaterMill Asset Management Corp. · Sole voting: 0 · Shared voting: 434,229 · Sole dispositive: 0 · Shared dispositive: 434,229 · SCHEDULE 13D/A, 2026-10-15
• Filed 2026-03-05 · Holder: Price Adrian · Percent: 8.6% · SCHEDULE 13D/A
• Filed 2026-02-24 · Holder: Price Adrian · Percent: 8.6% · SCHEDULE 13D/A
• Filed 2025-12-05 · Holder: Price Adrian intent stated · Percent: 8.6% · SCHEDULE 13D/A

Alaunos Therapeutics, Inc. has 11 Schedule 13D or 13G filings on record since 2025-07-01. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Stated intent

Intent stated in Item 4 Price Adrian

On December 4, 2025, Adrian Price sent a letter on behalf of the Reporting Persons to the Board of Directors of Alaunos Therapuetics, Inc. This letter requested the Board to appoint Gerald W.From Item 4 of the SCHEDULE 13D/A filed 2025-12-05

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Alaunos Therapeutics, Inc. and the warning signs.

See Alaunos Therapeutics, Inc.'s free Snapshot Watch Alaunos Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Alaunos Therapeutics, Inc. and the records around it.

Alaunos Therapeutics, Inc. elsewhere on the record

• Leadership changes Oct 2026
• Who owns it

Companies that share a holder

• Strategic EP, LLC also filed stake reports on 6 other companies: Earlyworks Co., Ltd. (Aug 2026), LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Jun 2026), GREENLAND MINES LTD (Mar 2026)
• Fairmount Funds Management LLC also filed stake reports on 13 other companies: SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026), Apogee Therapeutics, Inc. (Sep 2026)

Want the whole picture on Alaunos Therapeutics, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Alaunos Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Alaunos Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   12 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Alaunos Therapeutics, Inc. by CUSIP 98973P309 and gives its principal executive office as 501 E LAS OLAS BLVD, SUITE 300, FORT LAUDERDALE, FL 33301 (SCHEDULE 13D, 2026-10-15).

Purpose of Transaction (Item 4)

Pmgc Capital LLC

Item 4 is hereby replaced in its entirety as follows: Between June 16, 2025 and August 22, 2025, PMGC LLC sold all of Common Stock of the Issuer on the open market at prices ranging between $1.92 to $4.53 (such sales, in the aggregate, the "Transactions"). As of August 25, 2025, PMGC LLC's settlement date of the August 22, 2025 sales of the Issuer's Common Stock, the Reporting Persons are no longer beneficial owners or no longer may be deemed to be beneficial owners (as the case may be), of any shares of Common Stock.Item 4 of the SCHEDULE 13D/A filed 2025-09-05

Price Adrian

On February 24, 2026, counsel for Adrian Price sent a letter on behalf of the Reporting Persons to counsel of Alaunos Therapeutics, Inc. (the "Company"), and requested that the Company's counsel provide the letter to the Company's Board of Directors ("Board"). In this letter, Mr. Price proposed a private placement whereby HexagonONE Ltd, Alimenta Holding Limited and Krakatau Holding Limited (the "Investors") would purchase $7,000,000 of securities of the Company subject to mutually agreeable definitive documentation and customary closing conditions. The securities purchased by the Investors would be equity or equity-linked securities, with the purchase price to be negotiated in good faith, taking into account market conditions, the Company's liquidity needs, and long-term shareholder alignment. The Investors proposed that the private placement close as soon as practicable following Board approval and completion of documentation and shareholder approval (if required by Nasdaq rules). The letter requested the Board meet with Mr. Price within five business days to begin term sheet negotiation and due diligence. The letter also reiterated the Reporting Persons' nomination of Gerald Bruce to the Board and requested that the Board appoint Mr. Bruce as a director. The letter stated that if the Board did not engage meaningfully with Mr. Price within this five business day period, then the Reporting Persons may seek to purchase additional shares of the Company in the market or …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-03-05; the filing has the rest

Fairmount Funds Management LLC

The Reporting Persons own 19.99% of the Company in the aggregate, based upon the Company's aggregate outstanding shares as of September 30, 2026, plus the shares of Common Stock issued in the Financing (as defined below). The Reporting Persons' securities include (i) 687,789 shares of Common Stock and (ii) 171,000 shares of Common Stock issuable upon conversion of 171 shares of Series C Preferred Stock held directly by Co-Invest and exclude (i) 105,286,000 shares of Common Stock issuable upon conversion of 105,286 shares of Series B Preferred Stock held directly by Fund II, (ii) 52,239,000 shares of Common Stock issuable upon conversion of 52,239 shares of the Series C Preferred Stock held directly by Fund II and (iii) 16,554,000 shares of Common Stock issuable upon conversion of 16,554 shares of Series C Preferred Stock held directly by Co-Invest. The conversion of the shares of Series B Preferred Stock and Series C Preferred Stock is each subject to a beneficial ownership limitation of 19.99% of the outstanding shares of Common Stock. The securities exclude shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock and Series C Preferred Stock in excess of such beneficial ownership limitations. At such time as Fairmount and its affiliates beneficially own 9.0% or less of the shares of Common Stock, the beneficial ownership limitations with respect to the Series B Preferred Stock and Series C Preferred Stock will automatically reduce to 9.99%. …The first part of Item 4 of the SCHEDULE 13D filed 2026-10-15; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Alaunos Therapeutics, Inc.

Who owns Alaunos Therapeutics, Inc.?

On this page, 3 holders' latest ownership filings report 5% or more of Alaunos Therapeutics, Inc.: Fairmount Funds Management LLC (19.99%, Schedule 13D, filed 2026-10-15), Postma Robert W (9.99%, Schedule 13D/A, filed 2026-10-15) and Price Adrian (8.6%, Schedule 13D/A, filed 2026-03-05).

Who are the largest shareholders of Alaunos Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of Alaunos Therapeutics, Inc. on this page are Fairmount Funds Management LLC (19.99%), Postma Robert W (9.99%) and Price Adrian (8.6%).

When did Fairmount Funds Management LLC buy into Alaunos Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Fairmount Funds Management LLC on this page is the Schedule 13D, filed 2026-10-15, reporting 19.99%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Alaunos Therapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Alaunos Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Alaunos Therapeutics, Inc. is mentioned again
• Find former Alaunos Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes